Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity

Cell Death and Disease

Volumn 7, Issue 12, 2016, Pages

  Rulina, Anastasia V ^a,b,c   Mittler, Frédérique ^a,b,c   Obeid, Patricia ^a,b,c   Gerbaud, Sophie ^a,b,c   Guyon, Laurent ^a,b,c   Sulpice, Eric ^a,b,c   Kermarrec, Frédérique ^a,b,c   Assard, Nicole ^a,b,c   Dolega, Monika E ^a,b,c   Gidrol, Xavier ^a,b,c   Balakirev, Maxim Y ^a,b,c  

^a DIF   (France)

^b UNIV GRENOBLE ALPES   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CULLIN; CULLIN RING E3 LIGASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEDD8 PROTEIN; PROTEIN; PROTEIN P21; REPLICATION LICENSING FACTOR CDT1; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; WEE1 PROTEIN; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; CULL-RING LIGASE, HUMAN; CYCLOPENTANE DERIVATIVE; ERG PROTEIN, HUMAN; NEDD8 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL FATE; CELL PLASTICITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA STRAND BREAKAGE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LNCAP CELL LINE; M PHASE CELL CYCLE CHECKPOINT; NEDDYLATION; PRIORITY JOURNAL; PROSTATE CANCER; S PHASE CELL CYCLE CHECKPOINT; UPREGULATION; BIOLOGICAL MODEL; CELL LINEAGE; DRUG EFFECTS; GENE SILENCING; GENETIC TRANSCRIPTION; MALE; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL LINEAGE; CELL PLASTICITY; CELL PROLIFERATION; CELL SURVIVAL; CYCLOPENTANES; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; PYRIMIDINES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL REGULATOR ERG; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 85004088947     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.395     Document Type: Article

References (50)

1. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458: 438-444.
2. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-837.
3. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al. An inhibitor of NEDD8-Activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
4. Lydeard JR, Schulman BA, Harper JW. Building and remodelling Cullin-RING E3 ubiquitin ligases. EMBO Rep 2013; 14: 1050-1061.
5. Enchev RI, Schulman BA, Peter M. Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol 2015; 16: 30-44.
6. Zhao Y, Morgan MA, Sun Y. Targeting neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal 2014; 21: 2383-2400.
7. Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ et al. Phase I study of the investigational NEDD8-Activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors. Clin Cancer Res 2016; 22: 847-857.
8. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR et al. Phase I study of the novel investigational NEDD8-Activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma. Clin Cancer Res 2016; 22: 34-43.
9. Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, Ginel-Picardo A, Smith PG, Sacristan MP et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene 2013; 32: 1441-1451.
10. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-Targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010; 70: 10310-10320.
11. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-Activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011; 71: 3042-3051.
12. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011; 13: 561-569.
13. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L et al. MLN4924, a NEDD8-Activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010; 116: 1515-1523.
14. Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A et al. The Nedd8-Activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res 2014; 20: 1576-1589.
15. Yao WT, Wu JF, Yu GY, Wang R, Wang K, Li LH et al. Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death Dis 2014; 5: e1059.
16. Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D et al. The Nedd8-Activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 2012; 72: 3360-3371.
17. Zhao Y, Xiong X, Jia L, Sun Y. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis 2012; 3: e386.
18. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
19. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines-part 1. J Urol 2005; 173: 342-359.
20. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009; 106: 3964-3969.
21. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19: 664-678.
22. Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U et al. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discov 2015; 5: 550-563.
23. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011; 17: 5638-5648.
24. Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 2009; 69: 4974-4982.
25. Mullenders J, von der Saal W, van Dongen MM, Reiff U, van Willigen R, Beijersbergen RL et al. Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res 2009; 15: 5811-5819.
26. Pierce NW, Lee JE, Liu X, Sweredoski MJ, Graham RL, Larimore EA et al. Cand1 promotes assembly of new SCF complexes through dynamic exchange of F box proteins. Cell 2013; 153: 206-215.
27. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
28. Uhlén M, Björling E, Agaton C, CA-K Szigyarto, Amini B, Andersen E et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005; 4: 1920-1932.
29. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev 1999; 13: 270-283.
30. Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res 2013; 73: 6068-6079.
31. Emerling BM, Weinberg F, Liu J-L, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci USA 2008; 105: 2622-2627.
32. Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer. BJU Int 2014; 114: 168-176.
33. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R et al. Activation of NF-{kappa}B by TMPRSS2/ERG fusion isoforms through Toll-like receptor-4. Cancer Res 2011; 71: 1325-1333.
34. Tian F, Zhou P, Kang W, Luo L, Fan X, Yan J et al. The small-molecule inhibitor selectivity between IKK α and IKK β kinases in NF-κ B signaling pathway. J Recept Sig Transd 2015; 35: 307-318.
35. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, Mclauchlan H et al. The selectivity of protein kinase inhibitors: A further update. Biochem J 2007; 408: 297-315.
36. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012; 18: 892-901.
37. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
38. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 2002; 13: 1-11.
39. Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/beta-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate 2014; 74: 1118-1131.
40. Kokontis JM, Lin HP, Jiang SS, Lin CY, Fukuchi J, Hiipakka RA et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. PLoS ONE 2014; 9: e109170.
41. Gan W, Dai X, Lunardi A, Li Z, Inuzuka H, Liu P et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol Cell 2015; 59: 917-930.
42. An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X et al. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol Cell 2015; 59: 904-916.
43. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008; 68: 8516-8524.
44. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-Type SPOP, but not prostate-cancer-Associated mutants. Cell Rep 2014; 6: 657-669.
45. Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res 2014; 74: 5631-5643.
46. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
47. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.
48. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56: 237-244.
49. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela R, Pienta KJ. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In vivo 2001; 15: 157-162.
50. Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB et al. Evaluation of ERG responsive proteome in prostate cancer. Prostate 2014; 74: 70-89.